Final Soraya Analysis Supports Mirvetuximab Soravtansine In Ovarian Treatment with the folate receptor alpha (frα) targeted antibody drug conjugate mirvetuximab soravtansine (mirv) benefited patients with frα high platinum resistant ovarian cancer (proc) regardless of the number of prior lines of therapy, according to new data from the soraya study. Soraya is a single arm, phase ii study evaluating efficacy and safety of mirv in patients with proc. methods: soraya enrolled frα high patients with proc who had received one to three prior therapies, including required bevacizumab.
Soraya Shows Consistent Safety Profile For Mirvetuximab Soravtansine In Objective: the single arm, phase ii soraya trial (nct04296890) of mirvetuximab soravtansine gynx in folate receptor alpha (frα) high platinum resistant ovarian cancer (n=105 (efficacy evaluable)) met its primary endpoint with an objective response rate of 32.4% (95% ci, 23.6 to 42.2). here we report final soraya trial results for overall. Mirv is the first biomarker directed therapy demonstrating anti tumor activity in pts with frα high proc. these results support the clinically meaningful impact mirv has for pts with frα high proc, irrespective of prior therapies or dose modifications. clinical trial information: nct04209855. Clinically meaningful responses were demonstrated in subgroup analyses evaluating the sequencing of mirvetuximab soravtansine gynx (elahere) in patients with folate receptor alpha–high. Platinum resistant epithelial ovarian cancer (proc).mirvetuximab soravtansine (mirv) is an antibody drug conjugate targeting folate receptora (fra). soraya is a single arm, phase ii study evaluating efficacy and safety of mirv in patients with proc. methods soraya enrolled fra high patients with proc who had received one to three prior therapies,.
Soraya Trial Mirvetuximab Soravtansine Improves Response Rate In Drug Clinically meaningful responses were demonstrated in subgroup analyses evaluating the sequencing of mirvetuximab soravtansine gynx (elahere) in patients with folate receptor alpha–high. Platinum resistant epithelial ovarian cancer (proc).mirvetuximab soravtansine (mirv) is an antibody drug conjugate targeting folate receptora (fra). soraya is a single arm, phase ii study evaluating efficacy and safety of mirv in patients with proc. methods soraya enrolled fra high patients with proc who had received one to three prior therapies,. Our results indicated that the efficacy of mirvetuximab soravtansine in treating recurrent oc with fra positive expression was satisfactory, and the safety was tolerable. the pooled results showed an orr of 0.36 and a pooled dcr of 0.88. Clinicians now have more nuanced information on how the antibody drug conjugate mirvetuximab soravtansine (elahere, immunogen) works in patients with folate receptor alpha high (frα high). Conclusion these results support the clinically meaningful efficacy of mirvetuximab soravtansine gynx in frα expressing platinum resistant ovarian cancer, irrespective of prior treatment or.